We revised our 142 CML patients' samples in light of the transcript variants. Indeed, a difference was appreciable considering all the 512 samples collected throughout the duration of the study and evaluating the detectability of BCR-ABL1 by qPCR. e13a2 samples presented a higher rate (115/205) of detection compared with e14a2 ones (144/307; P = 0.0367). No difference was appreciable in terms of dPCR quantification, neither for fluorescence intensity, as considered by Kjaer et al, nor for absolute level of transcript
Variant-specific discrepancy when quantitating {BCR}-{ABL}1 e13a2 and e14a2 transcripts using the Europe Against Cancer {qPCR} assay. Is {dPCR} the key?
Massimiliano Bonifacio;
2019-01-01
Abstract
We revised our 142 CML patients' samples in light of the transcript variants. Indeed, a difference was appreciable considering all the 512 samples collected throughout the duration of the study and evaluating the detectability of BCR-ABL1 by qPCR. e13a2 samples presented a higher rate (115/205) of detection compared with e14a2 ones (144/307; P = 0.0367). No difference was appreciable in terms of dPCR quantification, neither for fluorescence intensity, as considered by Kjaer et al, nor for absolute level of transcript
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
